Gene therapy's growing pains.
Marshall
E
E
D000243:Adenosine Deaminase / Q000172:deficiency / Q000235:genetics / Q000627:therapeutic use; D026683:Advisory Committees; D002986:Clinical Trials as Topic / Q000191:economics; D017321:Clinical Trials, Phase I as Topic; D004274:DNA, Recombinant; D004345:Drug Industry / Q000191:economics; D035082:Federal Government; D030342:Genetic Diseases, Inborn; D015316:Genetic Therapy; D005822:Genetic Vectors; D033161:Government Regulation; D006801:Humans; D009316:National Institutes of Health (U.S.) / Q000458:organization & administration; D009369:Neoplasms / Q000628:therapy; D012109:Research Support as Topic; D016511:Severe Combined Immunodeficiency / Q000628:therapy; D014481:United States
D004274:DNA, Recombinant; D000243:Adenosine Deaminase